ETF Holdings Breakdown of IMVT

IMVT institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-29	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	52,315	USD 840,179
2025-09-29	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	9,820	USD 157,709
2025-09-29	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	98,847	USD 1,587,483 -1.1%
2025-09-29	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	98,847	USD 1,587,483
2025-09-29	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	407	USD 6,536 -1.1%
Total =		260,236	USD 4,179,390

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with IMVT

Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the […] - 2025-08-26 04:26:49

Bank of America Lowers Immunovant (NASDAQ:IMVT) Price Target to $30.00

Immunovant (NASDAQ:IMVT – Get Free Report) had its price objective reduced by equities research analysts at Bank of America from $33.00 to $30.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective would suggest a potential upside of 88.80% from the stock’s […] - 2025-08-14 03:07:05

Immunovant, Inc. (NASDAQ:IMVT) Receives $36.40 Average Price Target from Analysts

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the […] - 2025-08-04 02:42:53

Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $38.33

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The […] - 2025-07-10 02:50:51

Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the […] - 2025-06-12 05:18:48

ProShare Advisors LLC Buys 3,681 Shares of Immunovant, Inc. (NASDAQ:IMVT)

ProShare Advisors LLC boosted its position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 23,300 shares of the company’s stock after purchasing an additional 3,681 shares during the period. ProShare Advisors LLC’s holdings in Immunovant were worth $577,000 as of its most recent filing […] - 2025-05-26 05:18:59

Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-23 05:00:51

Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 8.4% in the fourth quarter, Holdings Channel reports. The firm owned 67,669 shares of the company’s stock after buying an additional 5,234 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Immunovant were […] - 2025-05-22 04:48:46

The Manufacturers Life Insurance Company Sells 772 Shares of Immunovant, Inc. (NASDAQ:IMVT)

The Manufacturers Life Insurance Company lowered its stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 2.1% during the fourth quarter, HoldingsChannel reports. The firm owned 35,908 shares of the company’s stock after selling 772 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Immunovant were worth $889,000 as of its […] - 2025-05-15 04:45:06

Invesco Ltd. Lowers Holdings in Immunovant, Inc. (NASDAQ:IMVT)

Invesco Ltd. reduced its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 15.2% in the fourth quarter, Holdings Channel reports. The firm owned 504,032 shares of the company’s stock after selling 90,210 shares during the period. Invesco Ltd.’s holdings in Immunovant were worth $12,485,000 at the end of the most recent reporting […] - 2025-04-22 04:57:06

Geode Capital Management LLC Purchases 4,094 Shares of Immunovant, Inc. (NASDAQ:IMVT)

Geode Capital Management LLC grew its position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 0.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,515,020 shares of the company’s stock after acquiring an additional 4,094 shares during the quarter. Geode […] - 2025-04-16 04:39:00

Norges Bank Buys Shares of 637,947 Immunovant, Inc. (NASDAQ:IMVT)

Norges Bank purchased a new position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 637,947 shares of the company’s stock, valued at approximately $15,802,000. A number of other large investors have also […] - 2025-04-08 04:46:59

Teacher Retirement System of Texas Acquires 2,373 Shares of Immunovant, Inc. (NASDAQ:IMVT)

Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,203 shares of the company’s stock after acquiring an additional 2,373 shares during the quarter. […] - 2025-04-01 04:44:44

Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $41.00

Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been given a consensus recommendation of “Buy” by the ten analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the […] - 2025-04-01 02:40:43

HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT)

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $51.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 159.01% from the company’s previous close. Several other […] - 2025-03-21 04:42:50

Guggenheim Reaffirms Buy Rating for Immunovant (NASDAQ:IMVT)

Guggenheim reiterated their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a report issued on Monday morning,Benzinga reports. A number of other brokerages have also issued reports on IMVT. Cantor Fitzgerald upgraded shares of Immunovant to a “strong-buy” rating in a research report on Tuesday, March 4th. Jefferies Financial Group assumed coverage […] - 2025-03-11 04:40:47

Immunovant, Inc. (NASDAQ:IMVT) Receives $43.55 Consensus Target Price from Analysts

Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy […] - 2025-03-07 04:43:06

Immunovant (NASDAQ:IMVT) Coverage Initiated at Jefferies Financial Group

Equities researchers at Jefferies Financial Group began coverage on shares of Immunovant (NASDAQ:IMVT – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set a “hold” rating and a $20.00 price target on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 8.17% […] - 2025-03-05 05:04:58

Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO)

Immunovant (NASDAQ:IMVT – Get Free Report) and OKYO Pharma (NASDAQ:OKYO – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Profitability This table compares Immunovant and OKYO Pharma’s net […] - 2025-03-05 04:20:53

Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. trimmed its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 16.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 791,863 shares of the company’s stock after selling 159,261 shares during the quarter. Principal Financial Group Inc.’s holdings in Immunovant were worth $19,614,000 as of its most recent […] - 2025-02-25 06:48:54

Guggenheim Cuts Immunovant (NASDAQ:IMVT) Price Target to $44.00

Immunovant (NASDAQ:IMVT – Get Free Report) had its price target dropped by equities researchers at Guggenheim from $46.00 to $44.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 127.51% from the company’s […] - 2025-02-12 06:46:57

Immunovant, Inc. (NASDAQ:IMVT) Receives $47.00 Consensus PT from Brokerages

Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been assigned an average recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating […] - 2025-02-12 06:09:06

Immunovant (NASDAQ:IMVT) Sets New 1-Year Low on Disappointing Earnings

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) shares hit a new 52-week low during trading on Monday following a weaker than expected earnings announcement. The stock traded as low as $19.82 and last traded at $19.60, with a volume of 702620 shares trading hands. The stock had previously closed at $20.41. The company reported ($0.76) […] - 2025-02-12 04:14:58

Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by KBC Group NV

KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,099 shares of the company’s stock after buying an additional 1,163 shares during the quarter. KBC Group NV’s […] - 2025-02-10 16:30:58

Back to Listing

Disclaimer